dc.contributor.author | Tuzer, Can | |
dc.contributor.author | Terzioglu, Kadriye | |
dc.date.accessioned | 2023-02-21T07:44:23Z | |
dc.date.available | 2023-02-21T07:44:23Z | |
dc.identifier.citation | Tuzer C., Terzioglu K., "Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, cilt.183, ss.651-661, 2022 | |
dc.identifier.issn | 1018-2438 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_0c44cbd3-88fe-4dce-a08b-5e0914d37fc6 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/186062 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/0c44cbd3-88fe-4dce-a08b-5e0914d37fc6/file | |
dc.identifier.uri | https://doi.org/10.1159/000521709 | |
dc.description.abstract | Introduction: The role of autoimmunity and other preexisting risky conditions in hypersensitivity reactions (HSRs) to COVID-19 vaccines seems unclear. The aim of the study was to investigate the autoimmunity and preexisting risky conditions in HSRs to COVID-19 vaccines. Methods: The patients aged >= 18 years with a history of HSR to CoronaVac or Pfizer-BioNTech COVID-19 vaccines within 24 h in 2 tertiary centers were assessed. The patients were divided according to the type of vaccine which they showed immediate-type (<4 h) HSR to (group A1 for CoronaVac and group B1 for Pfizer-BioNTech). Equal number of subjects who did not show HSR to two doses of either CoronaVac or Pfizer-BioNTech was recruited into the study as control groups (group A2 for CoronaVac and group B2 for Pfizer-BioNTech). The autologous serum skin test (ASST) was performed on patient and control groups. Later, the demographic, clinical, and laboratory features were compared between groups. Results: A total number of 27 patients were included in the study. Subjects with chronic spontaneous urticaria (CSU) were more frequent in group B1 than in group B2 (p:0.041). In addition to CSU, the presence of HSRs to drugs was higher in group A1 than in A2 (both p:0.007). The presence of autoimmunity and autoimmune diseases, positivity of antithyroid peroxidase antibody, and ASST were less in group A2 than in A1 (p:0.015, p:0.048, p:0.048, and p:0.037). Additionally, COVID-19 infection history was less in group A2 than in A1 (p:0.037). Discussion/Conclusion: Type IIb autoimmunity seems to play a role in immediate type HSRs to the CoronaVac vaccine as previously shown in autoimmune CSU and multidrug hypersensitivity. | |
dc.language.iso | eng | |
dc.subject | Temel Bilimler | |
dc.subject | İmmünoloji ve Alerji | |
dc.subject | Genel İmmünoloji ve Mikrobiyoloji | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | İmmünoloji | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ALERJİ | |
dc.title | Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines | |
dc.type | Makale | |
dc.relation.journal | INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY | |
dc.contributor.department | Batman Res & Educ Hosp , , | |
dc.identifier.volume | 183 | |
dc.identifier.startpage | 651 | |
dc.identifier.endpage | 661 | |
dc.contributor.firstauthorID | 3456531 | |